{"filing":{"accession_number":"0000718937-26-000036","cik":"0000718937","ticker":"STAA","company_name":"STAAR SURGICAL CO","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"staa-20260812.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/718937/000071893726000036/staa-20260812.htm"},"events":[{"id":27148,"run_id":24725,"accession_number":"0000718937-26-000036","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"STAAR Surgical published a press release on August 12, 2026 reporting second quarter 2026 financial results for the quarter ended July 3, 2026, disclosing net sales of $93.5 million (up 111% year-over-year), net income of $8.1 million ($0.16 per diluted share), and adjusted EBITDA of $20.0 million, with material improvements in revenue, profitability, and gross margin.","company_name":"STAAR SURGICAL CO","ticker":"STAA","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28551,"accession_number":"0000718937-26-000036","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"STAAR Surgical published a press release on August 12, 2026 reporting financial results for the quarter ended July 3, 2026, disclosing net sales of $93.5 million (up 111% Y/Y), net income of $8.1 million ($0.16 EPS), and adjusted EBITDA of $20.0 million. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, with material improvements in revenue, profitability, and gross margin that would affect a reasonable investor's assessment of the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:06:51.311895+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28552,"accession_number":"0000718937-26-000036","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses STAAR Surgical's second quarter 2026 financial results, including net sales of $93.5 million (up 111% Y/Y), net income of $8.1 million ($0.16 per diluted share), and adjusted EBITDA of $20.0 million. Exhibit 99.1 contains a comprehensive earnings release with detailed financial performance metrics, regional breakdowns, and management commentary. This is a material earnings disclosure that would significantly affect a reasonable investor's assessment of the company's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:06:51.311895+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28551,"accession_number":"0000718937-26-000036","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"STAAR Surgical published a press release on August 12, 2026 reporting financial results for the quarter ended July 3, 2026, disclosing net sales of $93.5 million (up 111% Y/Y), net income of $8.1 million ($0.16 EPS), and adjusted EBITDA of $20.0 million. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, with material improvements in revenue, profitability, and gross margin that would affect a reasonable investor's assessment of the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:06:51.311895+00:00","company_name":"STAAR SURGICAL CO","ticker":"STAA","filing_date":"2026-08-12"},{"id":28552,"accession_number":"0000718937-26-000036","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses STAAR Surgical's second quarter 2026 financial results, including net sales of $93.5 million (up 111% Y/Y), net income of $8.1 million ($0.16 per diluted share), and adjusted EBITDA of $20.0 million. Exhibit 99.1 contains a comprehensive earnings release with detailed financial performance metrics, regional breakdowns, and management commentary. This is a material earnings disclosure that would significantly affect a reasonable investor's assessment of the company's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:06:51.311895+00:00","company_name":"STAAR SURGICAL CO","ticker":"STAA","filing_date":"2026-08-12"}]}